Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain ...

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Docetaxel is a standard treatment for metastatic castration-resistant prostate ...

Survival curves for men treated with and without add-on docetaxel converged with longer follow-up. Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized ...

The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...

Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study. Patients with prostate ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The addition of darolutamide to docetaxel ...

Please provide your email address to receive an email when new articles are posted on . The regimen reduced risk for death by 32.5%. Data derived from Smith MR, et al. Abstract 13. Presented at: ASCO ...

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...

Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Neoadjuvant docetaxel plus androgen deprivation therapy may further reduce biochemical recurrence risk compared with neoadjuvant hormonal therapy alone in patients with high-risk prostate cancer ...